All Type of News
Drug-price cut fiasco
Pharmaceutical firms are at a loss as to why the government is pushing ahead with the unreasonable policy, which will result in 2 trillion won in losses for the pharmaceutical industry.
On August 12, the government...
OTC’s DUR program hits snag
The government has hit a snag with its plan to introduce the planned Drug Utilization Review (DUR) program of over-the-drug (OTC) medicines from next month, with pharmacists reluctant to join the DUR system.
Pharma...
First intradermal influenza vaccine to be released
Sanofi-Pasteur Korea and Handok Pharmaceutical plan to launch IDflu 15 μg㎍ vaccine, the first intradermal (ID) microinjection influenza vaccine, from next month.
Vaccination via the ID route involves the administra...
7 drugmakers has 27 blockbuster drugs exceeding 10 billion won in first half
A total of 27 flagship products released by seven leading Korean drug firms recorded more than 10 billion won in the first-half sales, according to data released by Yakup.com.
The data showed that Dong-A Pharmaceut...
Pharmacists file suit to nullify restriction-free decision of 48 OTC drugs
A total of 60 pharmacists said yesterday that it filed a lawsuit against the Ministry of Health and Welfare to nullify the government's decision to allow customers easier access to comparatively safe medicines.
The...
More tax exemptions set for R&D spending
Starting from next March, the government seeks to expand tax exemptions for corporate investment in research and development (R&D) as part of efforts to stimulate state-run and private companies’ R&D spending in the e...
Pharmacists challenge DUR program of OTC drugs
A dispute has arisen over the planned introduction next month of a government-imposed review of over-the-counter (OTC) medicines.
The Korean Pharmaceutical Association said yesterday it will boycott the Drug Utiliz...
Dong-A raises prices of Bayer’s OTC drugs
Dong-A Pharmaceutical Co. says it will significantly increase the prices of eight over-the-counter (OTC) products produced by Bayer between 13 and 30 percent to seek its profitable co-marketing business.
The compan...
Courts debate on PMS related rebate provision
A controversy surrounding the different rulings of the postmarketing surveillance (PMS) by a High or Supreme Court is growing.
Doctors and patients expect that when medications are prescribed correctly for labeled ...
Pharmaceutical firms spend 35.4% on promotion in first half
These days marketing activities have shrunken as the government expresses its strong will to punish both distributors and medical personnel if the latter is found to have received a “rebate” or kickback while purchasi...
